Study Touts PCSK9 Tx Add-on to Reach Lower LDL Target

ACC Conference Reporter

ESC Congress 2016 | ROME — Many patients with cardiovascular disease who fail to reach an adequate level of LDL cholesterol-lowering may benefit from a proprotein convertase subtilisin kexin type 9 (PCSK9) enzyme inhibitor as add-on therapy, a simulation study indicated. Read More >>>

Keywords: ESC Congress

< Back to Listings